Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination

Enzyme Mimics: Advances and Applications

(2016) Evelyn Kuah et al.   CHEMISTRY-A EUROPEAN JOURNAL

Immune-Related Adverse Events From Immune Checkpoint Inhibitors

(2016) KA Marrone et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prospects and progress of antibody-drug conjugates in solid tumor therapies

(2016) Serengulam V. Govindan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation

(2016) Zeljko M. Prijovich et al.   MOLECULAR PHARMACEUTICS

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

DNA repair targeted therapy: The past or future of cancer treatment?

(2016) Navnath S. Gavande et al.   PHARMACOLOGY & THERAPEUTICS

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy

(2016) C. Alix-Panabieres et al.   Cancer Discovery

Recombinant horseradish peroxidase variants for targeted cancer treatment

(2016) Günther Bonifert et al.   Cancer Medicine

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer

(2015) Na Young Jang et al.   BMC CANCER

Immuno-regulatory antibodies for the treatment of cancer

(2015) Jamie Honeychurch et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A Fusion Protein of RGD4C and β-Lactamase Has a Favorable Targeting Effect in Its Use in Antibody Directed Enzyme Prodrug Therapy

(2015) Hao Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents

(2015) Giulio Casi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity- An in silico Approach

(2015) L. N. Ramya et al.   PATHOLOGY & ONCOLOGY RESEARCH

Targeting DNA-PKcs increased anticancer drug sensitivity by suppressing DNA damage repair in osteosarcoma cell line MG63

(2015) Xin Li et al.   TUMOR BIOLOGY

Trastuzumab emtansine: mechanisms of action and drug resistance

(2014) Mark Barok et al.   BREAST CANCER RESEARCH

β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update

(2014) Isabelle Tranoy-Opalinski et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns

(2014) Xingwang Zhang et al.   Expert Opinion on Drug Metabolism & Toxicology

Evaluation of Cytotoxic Properties of a Cyclopamine Glucuronide Prodrug in Rat Glioblastoma Cells and Tumors

(2014) Souheyla Bensalma et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Dual-Porosity Hollow Nanoparticles for the Immunoprotection and Delivery of Nonhuman Enzymes

(2014) Inanc Ortac et al.   NANO LETTERS

Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs

(2014) J.N. Copp et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Characterization of a fusion protein of RGD4C and the ß-lactamase variant for antibody-directed enzyme prodrug therapy

(2014) Xiaoliang Zhou et al.   OncoTargets and Therapy

DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin

(2013) Wojciech M. Ciszewski et al.   BREAST CANCER RESEARCH AND TREATMENT

Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy

(2013) Thibaut Legigan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Selective Cancer Therapy by Extracellular Activation of a Highly Potent Glycosidic Duocarmycin Analogue

(2013) Kai-Chuan Chen et al.   MOLECULAR PHARMACEUTICS

Preclinical Evaluation of VB6-845: An Anti-EpCAM Immunotoxin with Reduced Immunogenic Potential

(2012) Joycelyn Entwistle et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Design and analysis of immune-evading enzymes for ADEPT therapy

(2012) D. C. Osipovitch et al.   PROTEIN ENGINEERING DESIGN & SELECTION

A Humanized Immunoenzyme with Enhanced Activity for Glucuronide Prodrug Activation in the Tumor Microenvironment

(2011) Kai-Chuan Chen et al.   BIOCONJUGATE CHEMISTRY

Synthesis and Biological Evaluation of Prodrugs Based on the Natural Antibiotic Duocarmycin for Use in ADEPT and PMT

(2011) Lutz F. Tietze et al.   CHEMISTRY-A EUROPEAN JOURNAL

Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT

(2011) Lutz F. Tietze et al.   CURRENT PHARMACEUTICAL DESIGN

An improved synthesis of lysosomal activated mustard prodrug for tumor-specific activation and its cytotoxic evaluation

(2011) Raghuramreddy Adidala et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Antibody–enzyme fusion proteins for cancer therapy

(2011) Carima Andrady et al.   Immunotherapy

Targeted Drug Delivery Using Immunoconjugates

(2011) Maria Valentina Pasquetto et al.   JOURNAL OF IMMUNOTHERAPY

Novel β-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapy

(2010) Girja S. Shukla et al.   JOURNAL OF DRUG TARGETING

Targeted Enzyme Prodrug Therapies

(2010) N. Schellmann et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas

(2009) T. Meyer et al.   CLINICAL CANCER RESEARCH

Targeting: The ADEPT Story So Far

(2009) K. Bagshawe   CURRENT DRUG TARGETS

Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer

(2009) S. Afshar et al.   MOLECULAR CANCER THERAPEUTICS

Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers☆

(2008) I SLOWING et al.   ADVANCED DRUG DELIVERY REVIEWS

Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy

(2008) Mickaël Thomas et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design and synthesis of a β-lactamase activated 5-fluorouracil prodrug

(2008) Ryan M. Phelan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Directed Evolution of a Lysosomal Enzyme with Enhanced Activity at Neutral pH by Mammalian Cell-Surface Display

(2008) Kai-Chuan Chen et al.   CHEMISTRY & BIOLOGY

Development of Pyrrolo[2,1-c][1,4]benzodiazepine β-Galactoside Prodrugs for Selective Therapy of Cancer by ADEPT and PMT

(2008) Ahmed Kamal et al.   ChemMedChem

Targeted therapy for cancer using PARP inhibitors

(2008) Christopher J Lord et al.   CURRENT OPINION IN PHARMACOLOGY

Benzyl Ether-Linked Glucuronide Derivative of 10-Hydroxycamptothecin Designed for Selective Camptothecin-Based Anticancer Therapy

(2008) Yu-Ling Leu et al.   JOURNAL OF MEDICINAL CHEMISTRY